These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 36192391)

  • 61. Molecular causes of the aberrant choline phospholipid metabolism in breast cancer.
    Glunde K; Jie C; Bhujwalla ZM
    Cancer Res; 2004 Jun; 64(12):4270-6. PubMed ID: 15205341
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Hypoxia inducible factor 1α-mediated LOX expression correlates with migration and invasion in epithelial ovarian cancer.
    Ji F; Wang Y; Qiu L; Li S; Zhu J; Liang Z; Wan Y; Di W
    Int J Oncol; 2013 May; 42(5):1578-88. PubMed ID: 23545606
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Downregulation of Choline Kinase-Alpha Enhances Autophagy in Tamoxifen-Resistant Breast Cancer Cells.
    Kim HS; Tian L; Jung M; Choi SK; Sun Y; Kim H; Moon WK
    PLoS One; 2015; 10(10):e0141110. PubMed ID: 26496360
    [TBL] [Abstract][Full Text] [Related]  

  • 64.
    Sırma Ekmekci S; Emrence Z; Abacı N; Sarıman M; Salman B; Ekmekci CG; Güleç Ç
    Turk J Haematol; 2020 Nov; 37(4):226-233. PubMed ID: 32586085
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Choline kinase down-regulation increases the effect of 5-fluorouracil in breast cancer cells.
    Mori N; Glunde K; Takagi T; Raman V; Bhujwalla ZM
    Cancer Res; 2007 Dec; 67(23):11284-90. PubMed ID: 18056454
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Pharmacodynamic markers for choline kinase down-regulation in breast cancer cells.
    Nimmagadda S; Glunde K; Pomper MG; Bhujwalla ZM
    Neoplasia; 2009 May; 11(5):477-84. PubMed ID: 19412432
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Lysine demethylase 2A promotes the progression of ovarian cancer by regulating the PI3K pathway and reversing epithelial‑mesenchymal transition.
    Lu DH; Yang J; Gao LK; Min J; Tang JM; Hu M; Li Y; Li ST; Chen J; Hong L
    Oncol Rep; 2019 Feb; 41(2):917-927. PubMed ID: 30483796
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Stanniocalcin 1 promotes metastasis, lipid metabolism and cisplatin chemoresistance via the FOXC2/ITGB6 signaling axis in ovarian cancer.
    Lin F; Li X; Wang X; Sun H; Wang Z; Wang X
    J Exp Clin Cancer Res; 2022 Apr; 41(1):129. PubMed ID: 35392966
    [TBL] [Abstract][Full Text] [Related]  

  • 69. CADM1 inhibits ovarian cancer cell proliferation and migration by potentially regulating the PI3K/Akt/mTOR pathway.
    Si X; Xu F; Xu F; Wei M; Ge Y; Chenge S
    Biomed Pharmacother; 2020 Mar; 123():109717. PubMed ID: 31865146
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Down-regulation of PADI2 prevents proliferation and epithelial-mesenchymal transition in ovarian cancer through inhibiting JAK2/STAT3 pathway in vitro and in vivo, alone or in combination with Olaparib.
    Liu L; Zhang Z; Zhang G; Wang T; Ma Y; Guo W
    J Transl Med; 2020 Sep; 18(1):357. PubMed ID: 32951601
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Biological basis of [¹¹C]choline-positron emission tomography in patients with breast cancer: comparison with [¹⁸F]fluorothymidine positron emission tomography.
    Contractor KB; Kenny LM; Stebbing J; Challapalli A; Al-Nahhas A; Palmieri C; Shousha S; Lewis JS; Hogben K; De Nguyen Q; Coombes RC; Aboagye EO
    Nucl Med Commun; 2011 Nov; 32(11):997-1004. PubMed ID: 21862943
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Targeting Leptin as a Therapeutic Strategy against Ovarian Cancer Peritoneal Metastasis.
    Wei X; Liu Y; Gong C; Ji T; Zhou X; Zhang T; Wan D; Xu S; Jin P; Yang X; Li X; Ma D; Yang Z; Gao Q
    Anticancer Agents Med Chem; 2017; 17(8):1093-1101. PubMed ID: 28002999
    [TBL] [Abstract][Full Text] [Related]  

  • 73. TRAP1 downregulation in human ovarian cancer enhances invasion and epithelial-mesenchymal transition.
    Amoroso MR; Matassa DS; Agliarulo I; Avolio R; Lu H; Sisinni L; Lettini G; Gabra H; Landriscina M; Esposito F
    Cell Death Dis; 2016 Dec; 7(12):e2522. PubMed ID: 27977010
    [TBL] [Abstract][Full Text] [Related]  

  • 74. LncRNA PSMA3-AS1 promotes cell proliferation, migration, and invasion in ovarian cancer by activating the PI3K/Akt pathway via the miR-378a-3p/GALNT3 axis.
    Xu Z; Jin H; Duan X; Liu H; Zhao X; Fan S; Wang Y; Yao T
    Environ Toxicol; 2021 Dec; 36(12):2562-2577. PubMed ID: 34520102
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Exposure of human breast cancer cells to the anti-inflammatory agent indomethacin alters choline phospholipid metabolites and Nm23 expression.
    Natarajan K; Mori N; Artemov D; Bhujwalla ZM
    Neoplasia; 2002; 4(5):409-16. PubMed ID: 12192599
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Molecular pathogenesis of esophageal squamous cell carcinoma: Identification of the antitumor effects of miR‑145‑3p on gene regulation.
    Shimonosono M; Idichi T; Seki N; Yamada Y; Arai T; Arigami T; Sasaki K; Omoto I; Uchikado Y; Kita Y; Kurahara H; Maemura K; Natsugoe S
    Int J Oncol; 2019 Feb; 54(2):673-688. PubMed ID: 30535463
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Nck1 promotes the progression of ovarian carcinoma by enhancing the PI3K/AKT/p70S6K signaling.
    Liu X; Zhang J; Duan Z; Feng X; Yu Y; He M; Tang L
    Hum Cell; 2020 Jul; 33(3):768-779. PubMed ID: 32166565
    [TBL] [Abstract][Full Text] [Related]  

  • 78. MicroRNA-489 targets XIAP to inhibit the biological progression of ovarian cancer via regulating PI3K/Akt signaling pathway and epithelial-to-mesenchymal transition.
    Jiang HW; Li L; Jiang P; Wang YF
    Eur Rev Med Pharmacol Sci; 2020 Apr; 24(8):4113-4122. PubMed ID: 32373947
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Value of 11C-choline PET/CT for lung cancer diagnosis and the relation between choline metabolism and proliferation of cancer cells.
    Li M; Peng Z; Liu Q; Sun J; Yao S; Liu Q
    Oncol Rep; 2013 Jan; 29(1):205-11. PubMed ID: 23124523
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Irisin/FNDC5 inhibits the epithelial-mesenchymal transition of epithelial ovarian cancer cells via the PI3K/Akt pathway.
    Zhu T; Zhang W; Zhang Y; Lu E; Liu H; Liu X; Yin S; Zhang P
    Arch Gynecol Obstet; 2022 Sep; 306(3):841-850. PubMed ID: 35156135
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.